Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 49, Issue 18, Pages 5552-5561Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm060495o
Keywords
-
Categories
Ask authors/readers for more resources
Ten complexes of general formula [ Ru( eta(6)-arene) Cl-2( L)], [ Ru( eta(6)-arene) Cl( L)(2)][ X], and [ Ru( eta(6)-arene)( L)(3)][ X](2) ( eta(6)-arene) benzene, p-cymene; L = imidazole, benzimidazole, N-methylimidazole, N-butylimidazole, N-vinylimidazole, N-benzoylimidazole; X = Cl, BF4, BPh4) have been prepared and characterized by spectroscopy. The structures of five representative compounds have been established in the solid state by single-crystal X-ray diffraction. All the new compounds were assessed by the same in vitro screening assays applied to [ imidazole-H][ trans-RuCl4( DMSO)( imidazole)] ( NAMI-A) and [ Ru( eta(6)-arene) Cl-2( 1,3,5-triaza-7-phosphaadamantane)] ( RAPTA) compounds. It was found that the new compounds show essentially the same order of cytotoxicity as the RAPTA compounds toward cancer cells. Several of the compounds were selective toward cancer cells in that they were less ( or not) cytotoxic toward nontumorigenic cells that are used to model healthy human cells. Thus, two of the compounds, [ Ru( eta(6)-p-cymene) Cl( vinylimid)(2)][ Cl] ( vinylimid = N-vinylimidazole) and [ Ru( eta(6)-benzene)( mimid)(3)][ BF4](2) ( mimid = N-methylimidazole), have been selected for a more detailed in vivo evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available